Unterehmen auf Watchlist setzen
TransMedics Group
ISIN: US89377M1099
WKN: A2PH5P
Curious about what AI knows about TransMedics Group? Just one click more
More AI Integrations
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

TransMedics Group · ISIN: US89377M1099 · PR Newswire (ID: 20250218NE21522)
18 Februar 2025 10:05PM

TransMedics to Present at Upcoming March Investor Conferences


ANDOVER, Mass., Feb. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Monday, March 3, 2025, at 11:50 a.m. EST and virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on Monday, March 17, 2025, at 9:20 a.m. EST.

Event: TD Cowen 45th Annual Health Care Conference

Date: Monday, March 3, 2025

Time: 11:50 a.m. EST

Event: Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Date: Monday, March 17, 2025

Time: 9:20 a.m. EST

A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:

Brian Johnston

Laine Morgan

332-895-3222

Investors@transmedics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-upcoming-march-investor-conferences-302379372.html

SOURCE TransMedics Group, Inc.

Visuelle Wertentwicklung / Kursverlauf · TransMedics Group
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
MIC: XNAS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942